{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:17:59Z","timestamp":1773249479213,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bulcan.2025.12.006","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:52:51Z","timestamp":1769086371000},"page":"362-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimisation de la prise en charge du cancer de la prostate m\u00e9tastatique sensible \u00e0 la castration\u00a0: des avanc\u00e9es th\u00e9rapeutiques aux soins personnalis\u00e9s"],"prefix":"10.1016","volume":"113","author":[{"given":"Yann","family":"Neuzillet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Balardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Faix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Raynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer","family":"Chaouachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.12.006_bib0460","first-page":"509","article-title":"Treatment landscape for metastatic castrate-sensitive prostate cancer: a review","volume":"15","author":"Meagher","year":"2023","journal-title":"Res Rep Urol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.12.006_bib0465","doi-asserted-by":"crossref","first-page":"102710","DOI":"10.1016\/j.fjurol.2024.102710","article-title":"French AFU Cancer Committee Guidelines\u00a0-\u00a0Update 2024-2026: Prostate cancer\u00a0-\u00a0Management of metastatic disease and castration resistance","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.12.006_bib0470","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3\u00a0trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16\u00a0Suppl.","key":"10.1016\/j.bulcan.2025.12.006_bib0475","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1200\/JCO.2025.43.16_suppl.5090","article-title":"8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.12.006_bib0480","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.9240","article-title":"2025\u00a0Canadian Urological Association-Canadian Uro-oncology Group Guideline: metastatic castration-naive and castration-sensitive prostate cancer (Update)","volume":"19","author":"So","year":"2025","journal-title":"Can Urol Assoc J"},{"issue":"8","key":"10.1016\/j.bulcan.2025.12.006_bib0485","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2025.12.006_bib0490","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2025.12.006_bib0495","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0500","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.bulcan.2025.12.006_bib0505","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.bulcan.2025.12.006_bib0510","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2025.12.006_bib0515","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2025.12.006_bib0520","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.bulcan.2025.12.006_bib0525","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3\u00a0study with a 2\u00d72\u00a0factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bulcan.2025.12.006_bib0530","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0535","first-page":"92","article-title":"Comparison of second-generation antiandrogens for the treatment of prostate cancer","volume":"12","author":"Park","year":"2022","journal-title":"J Hematol Oncol Pharm"},{"issue":"5\u00a0Suppl.","key":"10.1016\/j.bulcan.2025.12.006_bib0540","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.2025.43.5_suppl.66","article-title":"Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT)","volume":"43","author":"McKay","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5\u00a0Suppl.","key":"10.1016\/j.bulcan.2025.12.006_bib0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.2025.43.5_suppl.143","article-title":"Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): a subgroup analysis of ARASENS","volume":"43","author":"Carles","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0550","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.bulcan.2025.12.006_bib0555","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3\u00a0trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0560","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"10467","key":"10.1016\/j.bulcan.2025.12.006_bib0565","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3\u00a0study with a 2\u00d72\u00a0factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0570","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.12.006_bib0575","doi-asserted-by":"crossref","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate cancer in the US from 2000\u00a0to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"48","key":"10.1016\/j.bulcan.2025.12.006_bib0580","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.bulcan.2025.12.006_bib0585","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0590","doi-asserted-by":"crossref","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","article-title":"Assessment and management of cardiovascular risk factors among US veterans with prostate cancer","volume":"4","author":"Sun","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.bulcan.2025.12.006_bib0595","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.12.006_bib0600","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.21873\/anticanres.17164","article-title":"Prescription medications and overall survival in metastatic hormone sensitive prostate cancer","volume":"44","author":"Pickett","year":"2024","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0605","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1186\/s12913-022-08320-8","article-title":"The effect of clinical pharmacists\u2019 intervention in adverse drug reaction reporting: a retrospective analysis with a 9-year interrupted time series","volume":"22","author":"Lan","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0610","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/10781552241238198","article-title":"Review of drug-drug interactions in patients with prostate cancer","volume":"30","author":"Ruplin","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.bulcan.2025.12.006_bib0615","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/2279-042X.192461","article-title":"A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness","volume":"5","author":"Kheshti","year":"2016","journal-title":"J Res Pharm Pract"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0620","series-title":"Nubeqa: EPAR - Product Information","year":"2024"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0625","series-title":"Nubeqa: prescribing information","year":"2023"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0630","series-title":"Zytiga: EPAR - Product Information","year":"2024"},{"issue":"11","key":"10.1016\/j.bulcan.2025.12.006_bib0660","doi-asserted-by":"crossref","first-page":"103965","DOI":"10.1016\/j.esmoop.2024.103965","article-title":"Safety of solid oncology drugs in older patients: a narrative review","volume":"9","author":"Rousseau","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.bulcan.2025.12.006_bib0665","doi-asserted-by":"crossref","first-page":"103736","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer","volume":"9","author":"Bolek","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.bulcan.2025.12.006_bib0670","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0675","series-title":"Estimation nationale de l\u2019incidence et de la mortalit\u00e9 par cancer en France entre 1980\u00a0et 2012. \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim - Partie 1\u00a0: tumeurs solides","author":"Binder Foucard","year":"2013"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0680","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0685","doi-asserted-by":"crossref","first-page":"e390396","DOI":"10.1200\/EDBK_390396","article-title":"Management of prostate cancer in older adults","volume":"43","author":"Graham","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6\u00a0Suppl.","key":"10.1016\/j.bulcan.2025.12.006_bib0690","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2023.41.6_suppl.20","article-title":"Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy\u00b1docetaxel in older patients (\u226570\u00a0years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70\u00a0years): The PEACE-1\u00a0trial","volume":"41","author":"Mourey","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5\u00a0Suppl.","key":"10.1016\/j.bulcan.2025.12.006_bib0695","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2025.43.5_suppl.20","article-title":"Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)","volume":"43","author":"Fisher","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0700","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1186\/s12885-025-13961-z","article-title":"Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients","volume":"25","author":"Bonneau","year":"2025","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0705","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jgo.2019.04.016","article-title":"A systematic review on the association of the G8\u00a0with geriatric assessment, prognosis and course of treatment in older patients with cancer","volume":"10","author":"van Walree","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0710","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jjco\/hyac016","article-title":"Management of prostate cancer in older patients","volume":"52","author":"Narita","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2025.12.006_bib0715","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0720","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41391-019-0195-5","article-title":"A review of prostate cancer treatment impact on the CNS and cognitive function","volume":"23","author":"Ryan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0725","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ctrv.2014.03.003","article-title":"Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists","volume":"40","author":"Lange","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.bulcan.2025.12.006_bib0730","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.35210","article-title":"Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis","volume":"130","author":"Bou\u00e9","year":"2024","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.bulcan.2025.12.006_bib0735","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","article-title":"Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison","volume":"33","author":"Gonzalez","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0740","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bju.14666","article-title":"Androgen deprivation therapy for prostate cancer and risk of dementia","volume":"124","author":"Robinson","year":"2019","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0745","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0750","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0755","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2023.05.009","article-title":"A randomized, open-label, cross-over phase 2\u00a0trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer: patient preference and cognitive function in ODENZA","volume":"85","author":"Colomba","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0760","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eururo.2019.09.019","article-title":"Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study","volume":"77","author":"Thiery-Vuillemin","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0765","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1093\/geront\/gny126","article-title":"Can MoCA and MMSE be interchangeable cognitive screening tools? A systematic review","volume":"59","author":"Siqueira","year":"2019","journal-title":"Gerontologist"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0770","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S1470-2045(18)30938-0","article-title":"Pharmacologic management of cognitive impairment induced by cancer therapy","volume":"20","author":"Karschnia","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0775","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2019.03.007","article-title":"Impact of exercise training on physical and cognitive function among older adults: a systematic review and meta-analysis","volume":"79","author":"Falck","year":"2019","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0780","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2210-6","article-title":"Advanced cognitive training for breast cancer survivors: a randomized controlled trial","volume":"135","author":"Von Ah","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.bulcan.2025.12.006_bib0785","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1002\/cncr.33186","article-title":"Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: a 3-arm randomized trial","volume":"126","author":"Dos Santos","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0790","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neubiorev.2014.03.019","article-title":"A review of physical and cognitive interventions in aging","volume":"44","author":"Bamidis","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0795","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0800","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0148607116688881","article-title":"Malnutrition in patients with cancer: comparison of perceptions by patients, relatives, and physicians-results of the NutriCancer2012\u00a0study","volume":"42","author":"Gyan","year":"2018","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"10.1016\/j.bulcan.2025.12.006_bib0805","first-page":"3119","article-title":"The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)","volume":"30","author":"Raynard","year":"2022","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0810","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/01635581.2021.1884731","article-title":"Nutritional status and health-related quality of life in men with advanced castrate-resistant prostate cancer","volume":"74","author":"Cavka","year":"2022","journal-title":"Nutr Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2025.12.006_bib0815","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1464-410X.2010.09679.x","article-title":"A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"107","author":"Kim","year":"2011","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.bulcan.2025.12.006_bib0820","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1158\/1940-6207.CAPR-10-0229","article-title":"Body mass index prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis","volume":"4","author":"Cao","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1016\/j.bulcan.2025.12.006_bib0825","first-page":"225","article-title":"American Cancer Society prostate cancer survivorship care guidelines","volume":"64","author":"Skolarus","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2025.12.006_bib0830","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.21037\/tau.2019.11.02","article-title":"Selective androgen receptor modulators: the future of androgen therapy?","volume":"9","author":"Christiansen","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0835","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.15135","article-title":"Selective Androgen Receptor Modulators (SARMs) effects on physical performance: a systematic review of randomized control trials","volume":"102","author":"Wen","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0840","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1017\/S0029665123000046","article-title":"Physical activity and dietary considerations for prostate cancer patients: future research directions","volume":"82","author":"Hamblen","year":"2023","journal-title":"Proc Nutr Soc"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0845","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1249\/MSS.0000000000001454","article-title":"Exercise preserves physical function in prostate cancer patients with bone metastases","volume":"50","author":"Galv\u00e3o","year":"2018","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0850","doi-asserted-by":"crossref","first-page":"103801","DOI":"10.1016\/j.clon.2025.103801","article-title":"Sexual dysfunction in prostate cancer patients according to disease stage and treatment modality","volume":"41","author":"Kinnaird","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"11","key":"10.1016\/j.bulcan.2025.12.006_bib0855","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jsxm.2022.08.197","article-title":"Guidelines for sexual health care for prostate cancer patients: recommendations of an international panel","volume":"19","author":"Wittmann","year":"2022","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.bulcan.2025.12.006_bib0860","first-page":"149","article-title":"Sexual function in men undergoing androgen deprivation therapy","volume":"3","author":"Gryzinski","year":"2022","journal-title":"Androg Clin Res Ther"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0865","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco","year":"2023","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0870","article-title":"Androgen receptor pathway inhibitor monotherapy in prostate cancer: safety, oncologic outcomes, and quality of life\u2014a systematic review and meta-analysis","author":"Fazekas","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0875","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jsxmed\/qdad163","article-title":"consensus guidelines: PDE5\u00a0inhibitors and cardiac health","volume":"21","author":"Kloner","year":"2024","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.12.006_bib0880","doi-asserted-by":"crossref","first-page":"102842","DOI":"10.1016\/j.fjurol.2024.102842","article-title":"Therapeutic management of erectile dysfunction: the AFU\/SFMS guidelines","volume":"35","author":"Huyghe","year":"2025","journal-title":"Fr J Urol"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0885","doi-asserted-by":"crossref","first-page":"S1748","DOI":"10.1016\/j.annonc.2025.09.108","article-title":"LBA92 3-weekly docetaxel 75mg\/m2\u00a0vs 2-weekly docetaxel 50mg\/m2\u00a0in combination with darolutamide+ADT in patients with mHSPC: results from the randomised phase III ARASAFE trial","volume":"36","author":"Grimm","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.12.006_bib0890","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bulcan.2021.11.014","article-title":"\u00c9laboration d\u2019un programme d\u2019\u00e9ducation th\u00e9rapeutique d\u00e9di\u00e9 aux patients atteints d\u2019un cancer de la prostate sous hormonoth\u00e9rapie de nouvelle g\u00e9n\u00e9ration","volume":"109","author":"Cuenant","year":"2022","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2025.12.006_bib0895","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JU.0000000000002676","article-title":"Absolute prostate specific antigen after 6\u00a0months of androgen deprivation therapy is a predictor of overall and cancer-specific mortality in men with hormone-sensitive prostate Cancer","volume":"208","author":"Dursun","year":"2022","journal-title":"J Urol"},{"issue":"5\u00a0Suppl.","key":"10.1016\/j.bulcan.2025.12.006_bib0900","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/JCO.2025.43.5_suppl.147","article-title":"Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3\u00a0study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC)","volume":"43","author":"Azad","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.12.006_bib0905","doi-asserted-by":"crossref","first-page":"1391825","DOI":"10.3389\/fonc.2024.1391825","article-title":"EORTC 2238 \u201cDe-Escalate\u201d: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors","volume":"14","author":"Grisay","year":"2024","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2025.12.006_bib0455","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:14:50Z","timestamp":1773177290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0007455126000184"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.12.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimisation de la prise en charge du cancer de la prostate m\u00e9tastatique sensible \u00e0 la castration\u00a0: des avanc\u00e9es th\u00e9rapeutiques aux soins personnalis\u00e9s","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}